Unlocking the Potential of Acetazolamide: A Literature Review of an Adjunctive Approach in Heart Failure Management
Open Access
- 4 January 2024
- journal article
- review article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (1) , 288
Abstract
Background: Heart failure (HF) patients often experience persistent fluid overload despite standard diuretic therapy. The adjunctive use of acetazolamide, a carbonic anhydrase inhibitor, in combination with loop diuretics has shown promise in improving decongestion and diuretic efficacy. This literature review aims to analyze six studies evaluating the effectiveness of acetazolamide as an additive treatment for acute decompensated heart failure (ADHF) and its impact on various outcomes. Methods: We searched the PubMed database using the terms “acetazolamide heart failure”. We refined our search with specific filters (as shown our PRISMA flow diagram) and exclusion criteria, narrowing down our results to five studies. We included an extra study via expert recommendation, ultimately including six studies for comprehensive analysis. Results: The review highlights the positive effects of acetazolamide on decongestion, natriuresis, and diuresis in HF patients. However, it also showcases the limitations of these trials. Discussion: While the reviewed studies demonstrate the potential benefits of acetazolamide in enhancing decongestion and diuretic efficiency, there are limitations to consider, including small sample sizes, lack of blinding, and limited external validity. Further research is needed to confirm these findings, compare acetazolamide with other diuretic combinations, and explore its effects in a broader population of heart failure patients, including those in the United States. The use of acetazolamide in HF management warrants continued investigation to optimize its role in improving decongestion and patient outcomes.Keywords
This publication has 32 references indexed in Scilit:
- Acetazolamide as Add-on Diuretic Therapy in Exacerbations of Chronic Heart Failure: a Pilot StudyClinical Drug Investigation, 2017
- Efficacy and Safety of Spironolactone in Acute Heart FailureJAMA Cardiology, 2017
- Efficacy and Safety of Tolvaptan in Patients Hospitalized With Acute Heart FailureJACC, 2017
- Hypochloremia and Diuretic Resistance in Heart FailureCirculation: Heart Failure, 2016
- Everything we always wanted to know about furosemide but were afraid to askAmerican Journal of Physiology-Renal Physiology, 2016
- Diuretics: a reviewAnnals of Clinical Biochemistry: International Journal of Laboratory Medicine, 2012
- Effects of Tolvaptan, a Vasopressin Antagonist, in Patients Hospitalized With Worsening Heart FailureA Randomized Controlled TrialJAMA, 2004
- Mild Metabolic Alkalosis Impairs the Natriuretic Response to Bumetanide in Normal Human SubjectsClinical Science, 1998
- A volume-independent component to postdiuretic sodium retention in humans.Journal of the American Society of Nephrology, 1993
- Oral Administration of a Potent Carbonic Anhydrase Inhibitor (Diamox)New England Journal of Medicine, 1954